Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01073839|
Recruitment Status : Completed
First Posted : February 23, 2010
Last Update Posted : September 18, 2015
University of Zurich
Information provided by (Responsible Party):
Bernhard Pestalozzi, University of Zurich
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||August 2015|
|Actual Study Completion Date :||August 2015|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Siebenhüner AR, Seifert H, Bachmann H, Seifert B, Winder T, Feilchenfeldt J, Breitenstein S, Clavien PA, Stupp R, Knuth A, Pestalozzi B, Samaras P. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. BMC Cancer. 2018 Jan 11;18(1):72. doi: 10.1186/s12885-017-3967-0.